83 FR 4498 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 21 (January 31, 2018)

Page Range		4498-4499
FR Document		2018-01928

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S.

Federal Register, Volume 83 Issue 21 (Wednesday, January 31, 2018)

[Federal Register Volume 83, Number 21 (Wednesday, January 31, 2018)]
[Notices]
[Pages 4498-4499]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-01928]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S.

[[Page 4499]]

Government and are available for licensing in the U.S.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by emailing the 
indicated licensing contact at the National Heart, Lung, and Blood, 
Office of Technology Transfer and Development Office of Technology 
Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; 
telephone: 301-402-5579. A signed Confidential Disclosure Agreement may 
be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: This notice is in accordance with 35 U.S.C. 
209 and 37 CFR part 404 to achieve commercialization of results of 
federally-funded research and development. Foreign patent applications 
are filed on selected inventions to extend market coverage for 
companies and may also be available for licensing. A description of the 
technology follows.

Chimeric Antibodies Against Hepatitis B e-Antigen

    Description of Technology: The invention relates to recombinant 
chimeric rabbit/human monoclonal antibody fragments (Fabs) against 
hepatitis B Virus e-antigen (HBeAg), notably Fab me6. Viral hepatitis 
is the seventh leading cause of death worldwide. Hepatitis B core 
antigen (HBcAg) forms an icosahedral structure containing the viral 
genome. Both the HBcAg and the HBeAg of interest here are expressed by 
two different start codons of the viral C gene. Unlike the related 
HBcAg which activates type 1 T helper (Th1) cells leading to immune 
attack, the HBeAg activates Th2 cells which promote immune tolerance. 
The long-term persistence of HBeAg is associated with the development 
of hepatocellular carcinoma. Conversely, HBeAg seroconversion (from 
HBeAg carrier to anti-HBeAg carrier) is a marker for successful therapy 
of chronically infected patients. The presently phage display 
engineered antibody Fab me6 shows higher sensitivity and selectivity 
against HBeAg compared to three commercial diagnostics kits tested; 
additionally, it also inhibits capsid assembly which is essential for 
viral replication; furthermore, it can also be fully humanized and has 
potential for anti-hepatitis B virus therapeutic interventions.
    Potential Commercial Applications:
     Hepatitis B therapy.
     Hepatocellular carcinoma prophylaxis.
    Development Stage:
     In vitro data available.
    Inventors: Paul Winfield, Norman Watts, Alasdair Steven (all of 
NIAMS).
    Intellectual Property: HHS Reference No. E-192-2017/0-US-01.
     U.S. Provisional Patent Application 62/534,603 filed July 
19, 2017.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
shmilovm@nih.gov.
    Collaborative Research Opportunity: The National Institute of 
Environmental Health Sciences seeks statements of capability or 
interest from parties interested in collaborative research to further 
develop and evaluate, please contact Cecilia Pazman, Ph.D., Technology 
Development Specialist, Office of Technology Transfer, National Heart, 
Lung, and Blood Institute, Phone: (301) 594-4273; 
pazmance@nhlbi.nih.gov.

    Dated: January 25, 2018.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-01928 Filed 1-30-18; 8:45 am]
BILLING CODE 4140-01-P

4498 Federal Register / Vol. 83, No. 21 / Wednesday, January 31, 2018 / Notices

Dated: January 26, 2018. Place: Embassy Suites at the Chevy Chase Date: February 27, 2018.
Michelle Trout, Pavilion, 4300 Military Road NW, Time: 11:00 a.m. to 6:00 p.m.
Washington, DC 20015. Agenda: To review and evaluate grant
Program Analyst, Office of Federal Advisory
Contact Person: Careen K. Tang-Toth, applications.
Committee Policy.
Ph.D., Scientific Review Officer, Center for Place: National Institutes of Health, 6701
[FR Doc. 2018–01929 Filed 1–30–18; 8:45 am] Scientific Review, National Institutes of Rockledge Drive, Bethesda, MD 20892
BILLING CODE 4140–01–P Health, 6701 Rockledge Drive, Room 6214, (Virtual Meeting).
MSC 7804, Bethesda, MD 20892, (301)435– Contact Person: Ying-Yee Kong, Ph.D.,
3504, tothct@csr.nih.gov. Scientific Review Officer, Center for
DEPARTMENT OF HEALTH AND Name of Committee: Musculoskeletal, Oral Scientific Review, National Institutes of
HUMAN SERVICES and Skin Sciences Integrated Review Group; Health, 6701 Rockledge Drive, Room 5185,
Arthritis, Connective Tissue and Skin Study Bethesda, MD 20892, ying-yee.kong@nih.gov.
National Institutes of Health Section. Name of Committee: Center for Scientific
Date: February 27–28, 2018. Review Special Emphasis Panel; Member
Center for Scientific Review; Notice of Time: 8:00 a.m. to 5:00 p.m. Conflict: Topics in Nephrology.
Closed Meetings Agenda: To review and evaluate grant Date: February 27, 2018.
applications. Time: 1:00 p.m. to 6:00 p.m.
Pursuant to section 10(d) of the Place: Bethesda North Marriott Hotel & Agenda: To review and evaluate grant
Federal Advisory Committee Act, as Conference Center, 5701 Marinelli Road, applications.
Bethesda, MD 20852. Place: National Institutes of Health, 6701
amended, notice is hereby given of the Contact Person: Alexey Belkin, Ph.D.,
following meetings. Rockledge Drive, Bethesda, MD 20892
Scientific Review Officer, Center for
The meetings will be closed to the (Telephone Conference Call).
Scientific Review, National Institutes of
Contact Person: Jonathan K. Ivins, Ph.D.,
public in accordance with the Health, 6701 Rockledge Drive, Room 4102,
Scientific Review Officer, Center for
provisions set forth in sections Bethesda, MD 20817, 301–435–1786,
Scientific Review, National Institutes of
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., alexey.belkin@nih.gov.
Health, 6701 Rockledge Drive, Room 2190,
as amended. The grant applications and Name of Committee: Center for Scientific MSC 7850, Bethesda, MD 20892, (301) 594–
the discussions could disclose Review Special Emphasis Panel; 1245, ivinsj@csr.nih.gov.
confidential trade secrets or commercial Fellowships: Learning, Memory, Language,
Communication and Related, Neurosciences. Name of Committee: Center for Scientific
property such as patentable material, Date: February 27, 2018. Review Special Emphasis Panel; PAR–16–
and personal information concerning Time: 8:00 a.m. to 7:00 p.m. 380: Fundamental Mechanism of Affective
individuals associated with the grant Agenda: To review and evaluate grant and Decisional Process in Cancer Control.
applications, the disclosure of which applications. Date: February 27, 2018.
would constitute a clearly unwarranted Place: Pier 2620 Hotel, 2620 Jones St, San Time: 1:00 p.m. to 4:00 p.m.
Francisco, CA 94133. Agenda: To review and evaluate grant
invasion of personal privacy.
Contact Person: Susan Gillmor, Ph.D., applications.
Name of Committee: Oncology 2— Scientific Review Officer, National Institutes Place: National Institutes of Health, 6701
Translational Clinical Integrated Review of Health, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892
Group; Chemo/Dietary Prevention Study Rockledge Drive, Bethesda, MD 20892, 301– (Telephone Conference Call).
Section. 435–1730, susan.gillmor@nih.gov. Contact Person: Michael John McQuestion,
Date: February 22, 2018. Name of Committee: Center for Scientific Ph.D., Scientific Review Officer, Center for
Time: 8:00 a.m. to 5:00 p.m. Review Special Emphasis Panel; PAR 16– Scientific Review, National Institutes of
Agenda: To review and evaluate grant 245: Neural Regulation of Cancer. Health, 6701 Rockledge Drive, Room 3114,
applications. Date: February 27, 2018. Bethesda, MD 20892, 301–480–1276,
Place: Drury Inn & Suites San Antonio Time: 10:00 a.m. to 6:00 p.m. mike.mcquestion@nih.gov.
Riverwalk, 201 N St. Mary’s Street, San Agenda: To review and evaluate grant (Catalogue of Federal Domestic Assistance
Antonio, TX 78205. applications. Program Nos. 93.306, Comparative Medicine;
Contact Person: Svetlana Kotliarova, Ph.D., Place: National Institutes of Health, 6701 93.333, Clinical Research, 93.306, 93.333,
Scientific Review Officer, Center for Rockledge Drive, Bethesda, MD 20892 93.337, 93.393–93.396, 93.837–93.844,
Scientific Review, National Institutes of (Virtual Meeting). 93.846–93.878, 93.892, 93.893, National
Health, 6701 Rockledge Drive, Room 6214, Contact Person: Ola Mae Zack Howard, Institutes of Health, HHS)
Bethesda, MD 20892, 301–594–7945, Ph.D., Scientific Review Officer, Center for
kotliars@mail.nih.gov. Dated: January 25, 2018.
Scientific Review, National Institutes of
Name of Committee: Center for Scientific Health, 6701 Rockledge Drive, Room 4192, David Clary,
Review Special Emphasis Panel. MSC 7806, Bethesda, MD 20892, 301–451– Program Analyst, Office of Federal Advisory
Date: February 22–23, 2018. 4467, howardz@mail.nih.gov. Committee Policy.
Time: 8:00 a.m. to 5:00 p.m. Name of Committee: Center for Scientific [FR Doc. 2018–01820 Filed 1–30–18; 8:45 am]
Agenda: To review and evaluate grant Review Special Emphasis Panel; BILLING CODE 4140–01–P
applications. Fellowships: Cell Biology, Developmental
Place: Marriott Wardman Park Washington Biology, and Bioengineering.
DC Hotel, 2660 Woodley Road, NW, Date: February 27–28, 2018.
Washington, DC 20008. DEPARTMENT OF HEALTH AND
Time: 10:00 a.m. to 7:00 p.m.
Contact Person: Alok Mulky, Ph.D., Agenda: To review and evaluate grant HUMAN SERVICES
Scientific Review Officer, Center for applications.
Scientific Review (CSR), National Institutes Place: National Institutes of Health, 6701 National Institutes of Health
of Health (NIH), 6701 Rockledge Dr, Room Rockledge Drive, Bethesda, MD 20892.
4203, Bethesda, MD 20817, (301) 435–3566, Contact Person: Raj K. Krishnaraju, Ph.D., Government-Owned Inventions;
sradovich on DSK3GMQ082PROD with NOTICES

alok.mulky@nih.gov. Scientific Review Officer, Center for Availability for Licensing
Name of Committee: Center for Scientific Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6190, AGENCY: National Institutes of Health,
Review Special Emphasis Panel; Mechanisms
of Cancer Therapeutics 2. Bethesda, MD 20892, 301–435–1047, HHS.
Date: February 26–27, 2018. kkrishna@csr.nih.gov. ACTION: Notice.
Time: 8:00 a.m. to 5:00 p.m. Name of Committee: Center for Scientific
Agenda: To review and evaluate grant Review Special Emphasis Panel; Member SUMMARY: The inventions listed below
applications. Conflict: Integrative Neuroscience. are owned by an agency of the U.S.

VerDate Sep<11>2014 18:47 Jan 30, 2018 Jkt 244001 PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 E:\FR\FM\31JAN1.SGM 31JAN1

Federal Register / Vol. 83, No. 21 / Wednesday, January 31, 2018 / Notices 4499

Government and are available for Development Stage: DEPARTMENT OF HEALTH AND
licensing in the U.S. • In vitro data available. HUMAN SERVICES
FOR FURTHER INFORMATION CONTACT:
Inventors: Paul Winfield, Norman National Institutes of Health
Licensing information and copies of the
Watts, Alasdair Steven (all of NIAMS).
patent applications listed below may be
Intellectual Property: HHS Reference National Heart, Lung, and Blood
obtained by emailing the indicated
No. E–192–2017/0–US–01. Institute; Notice of Closed Meeting
licensing contact at the National Heart,
Lung, and Blood, Office of Technology • U.S. Provisional Patent Application Pursuant to section 10(d) of the
Transfer and Development Office of 62/534,603 filed July 19, 2017. Federal Advisory Committee Act, as
Technology Transfer, 31 Center Drive amended, notice is hereby given of a
Licensing Contact: Michael
Room 4A29, MSC2479, Bethesda, MD meeting of the NHLBI Mentored
20892–2479; telephone: 301–402–5579. Shmilovich, Esq, CLP; 301–435–5019;
Transition to Independence Review
A signed Confidential Disclosure shmilovm@nih.gov.
Committee.
Agreement may be required to receive Collaborative Research Opportunity: The meeting will be closed to the
copies of the patent applications. The National Institute of Environmental public in accordance with the
SUPPLEMENTARY INFORMATION: This Health Sciences seeks statements of provisions set forth in sections
notice is in accordance with 35 U.S.C. capability or interest from parties 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
209 and 37 CFR part 404 to achieve interested in collaborative research to as amended. The grant applications and
commercialization of results of further develop and evaluate, please the discussions could disclose
federally-funded research and contact Cecilia Pazman, Ph.D., confidential trade secrets or commercial
development. Foreign patent Technology Development Specialist, property such as patentable material,
applications are filed on selected Office of Technology Transfer, National and personal information concerning
inventions to extend market coverage Heart, Lung, and Blood Institute, Phone: individuals associated with the grant
for companies and may also be available (301) 594–4273; pazmance@ applications, the disclosure of which
for licensing. A description of the nhlbi.nih.gov. would constitute a clearly unwarranted
technology follows. invasion of personal privacy.
Dated: January 25, 2018.
Chimeric Antibodies Against Hepatitis Name of Committee: Heart, Lung, and
Michael Shmilovich, Blood Initial Review Group; NHLBI
B e-Antigen Senior Licensing and Patenting Manager, Mentored Transition to Independence
Description of Technology: The National Heart, Lung, and Blood Institute, Review Committee.
invention relates to recombinant Office of Technology Transfer and Date: March 8–9, 2018.
chimeric rabbit/human monoclonal Development. Time: 8:00 a.m. to 1:00 p.m.
antibody fragments (Fabs) against [FR Doc. 2018–01928 Filed 1–30–18; 8:45 am] Agenda: To review and evaluate grant
hepatitis B Virus e-antigen (HBeAg), applications.
BILLING CODE 4140–01–P
Place: The William F. Bolger Center, 9600
notably Fab me6. Viral hepatitis is the Newbridge Drive, Potomac, MD 20854.
seventh leading cause of death Contact Person: Giuseppe Pintucci, Ph.D.,
worldwide. Hepatitis B core antigen DEPARTMENT OF HEALTH AND Scientific Review Officer, Office of Scientific
(HBcAg) forms an icosahedral structure HUMAN SERVICES Review/DERA, National Heart, Lung, and
containing the viral genome. Both the Blood Institute, 6701 Rockledge Drive, Room
HBcAg and the HBeAg of interest here National Institutes of Health 7192, Bethesda, MD 20892, 301–435–0287,
are expressed by two different start Pintuccig@nhlbi.nih.gov.
codons of the viral C gene. Unlike the Center for Scientific Review; Amended (Catalogue of Federal Domestic Assistance
related HBcAg which activates type 1 T Notice of Meeting Program Nos. 93.233, National Center for
helper (Th1) cells leading to immune Sleep Disorders Research; 93.837, Heart and
attack, the HBeAg activates Th2 cells Notice is hereby given of a change in Vascular Diseases Research; 93.838, Lung
the meeting of the Skeletal Biology Diseases Research; 93.839, Blood Diseases
which promote immune tolerance. The and Resources Research, National Institutes
long-term persistence of HBeAg is Development and Disease Study of Health, HHS)
associated with the development of Section, February 8, 2018, 8:00 a.m. to
hepatocellular carcinoma. Conversely, February 9, 2018, 3:00 p.m., Westin Dated: January 26, 2018.
HBeAg seroconversion (from HBeAg Baltimore Washington Airport, 1100 Michelle Trout,
carrier to anti-HBeAg carrier) is a Old Elkridge Landing Road, Linthicum Program Analyst, Office of Federal Advisory
marker for successful therapy of Heights, MD, 21090 which was Committee Policy.
chronically infected patients. The published in the Federal Register on [FR Doc. 2018–01930 Filed 1–30–18; 8:45 am]
presently phage display engineered January 5, 2018, 83 FR PG 683. The BILLING CODE 4140–01–P
antibody Fab me6 shows higher meeting will be held on February 7,
sensitivity and selectivity against 2018 at 3:00 p.m. and end February 8,
HBeAg compared to three commercial DEPARTMENT OF HEALTH AND
2018 at 9:00 p.m. The meeting location
diagnostics kits tested; additionally, it HUMAN SERVICES
remains the same. The meeting is closed
also inhibits capsid assembly which is to the public.
essential for viral replication; National Institutes of Health
Dated: January 25, 2018.
sradovich on DSK3GMQ082PROD with NOTICES

furthermore, it can also be fully National Institute on Aging; Amended
humanized and has potential for anti- Melanie J. Pantoja,
Notice of Meeting
hepatitis B virus therapeutic Program Analyst, Office of Federal Advisory
interventions. Committee Policy. Notice is hereby given of a change in
Potential Commercial Applications: [FR Doc. 2018–01821 Filed 1–30–18; 8:45 am] the meeting of the National Advisory
• Hepatitis B therapy. BILLING CODE 4140–01–P
Council on Aging, January 23, 2018,
• Hepatocellular carcinoma 3:00 p.m. to January 24, 2018, 2:00 p.m.,
prophylaxis. National Institutes of Health, Building

VerDate Sep<11>2014 17:36 Jan 30, 2018 Jkt 244001 PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 E:\FR\FM\31JAN1.SGM 31JAN1

Document Created: 2018-01-31 00:58:56
Document Modified: 2018-01-31 00:58:56

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Licensing information and copies of the patent applications listed below may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.
FR Citation		83 FR 4498

83 FR 4498 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 21 (January 31, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health